Biotech startup 600and1, described as a unicorn in the longevity sector, has launched an ambitious initiative to decode and bioengineer the biology of aging, according to the company. The firm said that it plans to map the fundamental cellular and molecular processes that drive aging and then develop engineered solutions to intervene in those pathways.
According to the company, the initiative will leverage a large multidisciplinary team and internal research platform that integrates genomics, cell biology, AI and bioengineering to capture aging-related mechanisms across multiple cell types and tissues. The company claims this approach is distinct from therapies that focus on individual diseases and instead targets the systemic biology of aging.
600and1 said that it targets both the discovery of aging-modulating genes and pathways and the translation of those discoveries into engineered therapies, including cellular, genetic and molecular treatments designed to restore youthful function. The company outlined plans for multiple program areas spanning age‐related disease, tissue repair and longevity.
The company stated that the funding backing this effort reflects growing investor interest in the longevity sector and enables the startup to build infrastructure, recruit talent and accelerate product development. The company claims that its launch marks a significant step toward bringing engineered solutions for aging biology into clinical development.
